6 results
Primary Objective: To determine whether or not our newly developed MRA with accelerometer can measure the therapy-effect of the MRA by determining the correlation of the treatment-efficacy of an MRA measured by an integrated accelerometer built in…
The primary objective of this study is to evaluate the effects of SYR-322 and SYR-322coadministered with pioglitazone HC1 versus placebo on postprandial triglycerides in subjectswith type 2 diabetes.
The primary objective is to study the effect of a 16-week treatment with a PPAR-* agonist versus placebo on effectiveness of subsequent standard treatment with PEG-IFN and RBV, measured as SVR, in previously non-responders or relapsers with CHC…
The objective of the study is to evaluate the efficacy of the addition of SYR-322 (25 mg) to subjects who are inadequately controlled on pioglitazone HCl (30 mg) and metformin (*1500 mg or MTD).
The aim is to evaluate whether the use of eRFA prior to stenting prolongs stent patency in patients with biliary obstruction due to inoperable perihilar cholangocarcinoma.
It is hypothesized that eRFA leads to increased stent patency, fewer re-interventions, fewer (permanent) external drains, and consequently increased quality of life. The primary aim of the proposed pilot study is to evaluate whether eRFA is feasible…